Issues‎ > ‎Vol 7, issue 1‎ > ‎


Immunohistochemical Expression of BubR1 and Telomerase in Oral Squamous Cell Carcinoma

Balkees T. Garib* , Dena N. Mohammad* , Marwa A. Hamied*

* Department of Oral Diagnosis, College of Dentistry, Sulaimani University, Sulaimani, Iraq. 

Submitted: 08/02/2020; Accepted: 01/05/2020; Published 01/06/2020



Objective: Aberrant BubR1 and Telomerase expressions are considered as important markers in tumor progression and clinical outcome. This study purposed to describe, compare, and correlate the immunohistochemical expression of BubR1 and Telomerase in oral squamous cell carcinoma (OSCC).

Methods: Immunohistochemical staining was performed for 28 OSCC samples. The samples graded according to Bryne’s grading system. The reaction positivity, intracellular localization, and intensity were recorded. The expression distribution and mean-ranks of these markers were related to OSCC grades by Fisher’s exact and Kruskal Wallis tests. Finally, the correlation between them was achieved by Spearman’s rho test.

ResultsBubR1 was detected in 89.3% of OSCCs, equally within scores 2 and 3 (35.7%), presented with 50% faint intensity, and 64.3% cytoplasmic localization. Grade III had a significantly higher mean-rank of BubR1 scoring. Whereas Telomerase observed in 75% of OSCCs, mainly found at scores 2 and 3 (60.7%), and 42.9% was within the cytoplasm. Half of OSCCs had faint intensity. No significant differences reported in the mean-rank and stain intensity among the grades. There was no significant correlation between BubR1 and Telomerase expression.

Conclusions: OSCCs had high cytoplasmic BubR1 and telomerase expression that cannot ensure proper function. Mean-rank of BubR1 expression related to OSCC grading and being more in high grade. It determines the loss of differentiation and aggressiveness of OSCC. While the mean-rank of Telomerase did not relate to histopathological grading and considered an early event in carcinogenesis, it can use for the diagnostic approach of oral carcinogenesis. These markers have an independent role in cancer progression.


Keywords: BubR1, Telomerase, OSCC, Immunohistochemical.                                                                                                                                                                                                     Full Article - PDF                                                                                                                                                                                                                                   


1. Mao L, El-Naggar AK, Fan YH, Lee JS, Lippman SM, Kayser S. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res. 1996;56(24):5600-4.
2. Park HY, Jeon YK, Shin HJ, Kim IJ, Kang HC, Jeong SJ, et al. Differential promoter methylation may be a key molecular mechanism in regulating BubR1 expression in cancer cells. Exp Mol Med. 2007;39(2):195-204.
3. Lira RC, Miranda FA, Guimarães MC, Simões RT, Donadi EA, Soares CP et al. BUBR1 expression in benign oral lesions and squamous cell carcinomas: correlation with human papillomavirus. Oncol Rep. 2010;23(4):1027-36.
4. Boscolo-Rizzo P, Da Mosto MC, Rampazzo E, Giunco S, Del Mistro A, Menegaldo A et al. Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implication. Cancer Metastasis Rev. 2016;35(3):457-74.
5. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V , Cech TR. Reverse transcriptase motifs in the catalytic subunit of Telomerase. Science. 1997;276(5312):561-7.
6. Raju KL, Haragannavar VC, Patil S, Rao RS, Nagaraj T, Augustine D et al. Expression of hTERT in oral submucous fibrosis and oral squamous cell carcinoma- an immunohistochemical analysis. Pathol Oncol Res. 2019:1-10.
7. Rastogi V, Puri N, Mishra S, Sharma R, Yadav L, Sabharwal R. Dilemmas in grading epidermoid carcinoma. Int J Head Neck Sur. 2014;5(1):9-14.
8. Maciejczyk A, Szelachowska J, Czapiga B, Matkowski R, Hałoń A, Györffy B, et al. Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis. J Histochem Cytochem. 2013;61(5):330-9.
9. Maraei AA, Hatta AZ, Shiran MS, Tan GC. Human telomerase reverse transcriptase expression in ovarian tumors. Indian J Pathol Microbiol. 2012;55(2):187-91.
10. Al Talabani NG, Gaphor SM, Abdul Wahab RH. Serum and salivary levels of proinflammatory cytokines as potential biomarkers in the diagnosis of oral squamous cell carcinoma. J Baghdad Coll Dent. 2013;21(1):60-5.
11. Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol. 2010;2:13- 21.
12. AlvesAM,CorreaMB,SilvaKDD,AraújoLMA, Vasconcelos ACU, Gomes APN et al. Demographic and clinical profile of oral squamous cell carcinoma from a service-based population. Braz Dent J. 2017;28(3):301-6.
13. Jainkittivong A, Swasdison S, Thangpisityotin M, Langlais RP. Oral squamous cell carcinoma: a clinicopathological study of 342 Thai cases. J Contemp Dent Pract. 2009;10(5):E033-40.
14. Silva P, Barbosa J, Nascimento AV, Faria J, Reis R, Bousbaa H. Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint. Cell Prolif. 2011;44(5):391-400.
15. Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy, and tumorigenesis. Nat Rev Mol Cell Biol. 2009;10(7):478-87.
16. Hsieh PC, Chen YK, Tsai KB, Shieh TY, Chang YY, Chang JG et al. Expression of BUBR1 in human oral potentially malignant disorders and squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(2):257- 67.
17. Rizzardi C, Torelli L, Barresi E, Schneider M, Canzonieri V, Biasotto M et al. BUBR1 expression in oral squamous cell carcinoma and its relationship to tumor stage and survival. Head Neck. 2011;33(5):727-33.
18. Sravya T, Sivaranjani Y, Rao GV. Immunohistochemical expression of budding uninhibited by benzimidazole related 1 in leukoplakia and oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2016;20(1):71-7.
19. Rai A, Naikmasur VG, Sattur A. Quantification of telomerase activity in normal oral mucosal tissue and oral squamous cell carcinoma. Indian J Med Paediatr Oncol. 2016;37(3):183-8.
20. Carkic J, Nikolic N, Radojevic-Skodric S, Kuzmanovic-Pficer J, Brajovic G, Antunovic M et al. The role of tertclptm1l SNPs, hTERT expression and telomere length in the pathogenesis of oral squamous cell carcinoma. J Oral Sci. 2016;58(4):449-58.
21. Raghunandan BN, Sanjai K, Kumaraswamy J, Papaiah L, Pandey B, Jyothi BM (2016) Expression of human telomerase reverse transcriptase protein in oral epithelial dysplasia and oral squamous cell carcinoma: An immunohistochemical study. J Oral Maxillofac Pathol. 2016;20(1):96-101.
22. Miyazaki Y, Yoshida N, Nozaki T, Inoue H, Kikuchi K, Kusama K. Telomerase activity in the occurrence and progression of oral squamous cell carcinoma. J Oral Sci. 2015;57(4):295-303.
23. Kannan S, Tahara H, Yokozaki H, Mat hew B, Nalinakumari KR, Nair MK et al. Telomerase activity in premalignant and malignant lesions of human oral mucosa. Cancer epidemiol biomarkers prev. 1997;6(6):413-20.
24. Sumida T, Sogawa K, Hamakawa H, Sugita A, Tanioka H, Ueda N. Detection of telomerase activity in oral lesions. J Oral Pathol Med. 1998;27(3):111-5.
25. Palani J, Lakshminarayanan V , Kannan R. Immunohistochemical detection of human telomerase reverse transcriptase in oral cancer and pre-cancer. Indian J Dent Res. 2011;22(2):362-3.

Creative Commons License © The Authors, published by University of Sulaimani, College of Dentistry